PF-QII Analysis of Deep Brain Stimulation versus Levodopa-carbidopa Intestinal Gel: Real-world Differences in Patient Characteristics and Quality of Life Outcomes
Objective: To evaluate differences in demographics, disease characteristics, quality of life (QOL), and caregiver burden (CB) between deep brain stimulation (DBS) and levodopa-carbidopa intestinal gel…Temporal properties of resting-state functional MRI are associated with ON/OFF levodopa MDS-UPDRS III scores in patients with Parkinson’s disease
Objective: To explore the relationship between temporal resting-state functional magnetic resonance imaging (fMRI) properties and ON/OFF Levodopa motor performance scores in patients with Parkinson's disease…Daily Time-Course of Efficacy of Continuous Subcutaneous Infusion of Foslevodopa/foscarbidopa in Advanced Parkinson’s Disease Patients from a Phase 1b Study
Objective: Characterize and compare the time-course of Parkinson’s disease (PD) symptoms following 24h/day continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa and oral levodopa/carbidopa (LD/CD). Background: As…The influence of ANNK1/DRD2 haplotypes on the onset of complications of long-term levodopa therapy in Parkinson’s disease
Objective: To investigate an influence of selected polymorphisms in DRD2 and ANKK1 genes on the occurrence of complications of long-term levodopa therapy in Serbian PD…Technology-based therapy response and prognostic biomarkers in Parkinson’s disease: results from a prospective evaluation of a de novo PD patients’ cohort
Objective: To prospectively evaluate motor performances with technology-based objective measures (TOMs) in a cohort of PD patients in order to identify therapy response and prognostic…Motor, non-motor and cognitive correlates of carotid intima-media thickness in patients with Parkinson’s disease
Objective: To determine the correlation of carotid intima-media thickness (IMT) to motor, non-motor and cognitive scales in patients with Parkinson’s disease (PD). Background: Increased IMT…Real-World Data on the Use of Levodopa-Carbidopa Intestinal Gel in Patients with Advanced Parkinson’s Disease who are Treated with Deep Brain Stimulation: The PD-DUAL Study
Objective: To examine the use of oral anti-parkinsonian medications in advanced Parkinson’s disease (APD) patients who have a history of, or current treatment with deep…High levodopa plasma concentration in the acute levodopa challenge test predicts levodopa-induced dyskinesia in Parkinson’s disease
Objective: We aimed to investigate the correlation between levodopa pharmacokinetics and levodopa-induced dyskinesia (LID) in Parkinson’s disease (PD). Background: In patients with PD, pulsatile dopaminergic…Loss of Weight Associated with Levodopa / Carbidopa Intestinal Gel
Objective: To define the prevalence and severity of WL in patients of the Movement Disorders Unit of our center treated with LCIG and to analyze…Positive Correlations Between Quality of Life and Sleep Dysfunction in Advanced Parkinson’s Disease Patients Prior to and After 12 Months of Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis From the DUOGLOBE Study
Objective: To evaluate the relationship between sleep disturbances and quality of life (QoL) in advanced Parkinson’s disease (PD) patients both prior to and at month…
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- …
- 62
- Next Page »